Sign in to view content

Safety, Tolerability, and Efficacy of Tinlarebant: 24-Month Primary Outcomes of the Phase 2 Study in Adolescent Patients With Stargardt Disease

Quan Dong Nguyen, MD, MSc, FARVO, FASRS

Video
Published 2024

Related

Expert Panel: Pegcetacoplan Safety
Andre J. Witkin, MD
David A. Eichenbaum, MD, FASRS
Samuel Anthony Minaker, MD, MSc
Janani Singaravelu, MS, MD
Sunir J. Garg, MD, FACS, FASRS
Annual Meeting Talks
2024
Evaluation of 8 mg Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration: Results from the Phase 2 CANDELA Study
W. Lloyd Clark, MD, FASRS
Updates from the Field
2022
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss
Jennifer K. Sun, MD
Updates from the Field
2019

Category: Hereditary Retinal Disease & Genetics

See more